Genmab A/S has filed a CTA in Europe to start an open label Phase I/II clinical trial using HuMax-EGFr to treat patients suffering from head and neck cancer.

The trial is expected to include fewer than 40 patients, and will be a dose escalation study. The primary endpoint will be to assess the safety of the treatment and the secondary endpoint to assess the efficacy of HuMax-EGFr.

Genmab will work with the DAHANCA group (Danish Head and Neck Cancer Group), an organization which is in contact with all patients suffering from head and neck cancer in Denmark, in order to identify potential trial participants.